GIANT BIOGENE (02367) announced its performance in 2025 with a net profit attributable to the parent of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year.

GIANT BIOGENE (02367) announced its performance for the year 2025, with revenue of approximately 5.5185 billion yuan, a decrease of 0.4% year-on-year; gross profit of approximately 4.4334 billion yuan, a decrease of 2.5% year-on-year; profit attributable to owners of the parent company of approximately 1.915 billion yuan, a decrease of 7.2% year-on-year; adjusted net profit of approximately 1.96 billion yuan, a decrease of 8.9% year-on-year; basic earnings per share of 1.83 yuan, with a proposed final dividend of 0.5390 yuan per share and a special dividend of 0.6714 yuan per share. The announcement stated that overall revenue remained flat, mainly due to changes in sales of professional skin care products, with increased revenue from functional skin care products benefiting from the company's continued strengthening of marketing activities across all channels, as well as the continued strong sales of star products such as the Cana Bio-focus Repairing Cream and the successful launch of the Collagen King 3.0 after its upgrade; revenue from medical dressings declined slightly, mainly due to the company's efforts to maintain product pricing, actively strengthen channel sales control, which had some impact on short-term revenue scale. The decrease in gross profit was mainly due to the decrease in sales revenue and increase in sales costs.